Vycellix, Avectas partner for product development

By The Science Advisory Board staff writers

March 26, 2020 -- Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

The companies will partner on the use of Vycellix's RNA immunomodulator VY-M for immunodiscovery cell and gene therapy with Avectas' Solupore cell engineering platform to address the current limitations of cell-based therapies and the need to accelerate manufacturing processes, reduce manufacturing costs, and improve patient outcomes.

Vycellix and Avectas also are currently collaborating with NextGenNK, a newly established competence center for the development of next-generation natural killer cell-based cancer immunotherapies based at Karolinska Institutet in Stockholm, Sweden.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here